EGFR and cancer: Intriguingly, the high-throughput anti-cancer compound screening assays demonstrated that TFF3 inhibition by AMPC synergized most effectively with compounds targeting four distinct RTKs, EGFR, VEGFR, c-KIT, and c-MET in MDA-MB-361 and BT474 cells.